Brief: Ikena Oncology Shares Initial Positive Dose Escalation Data From IK-930 Phase I Trial And Reports Third Quarter 2023 Results

ImageneBio

09/11/2023 12:35

Nov 9 (Reuters) - Ikena Oncology Inc  IKNA.O :
    * IKENA ONCOLOGY SHARES INITIAL POSITIVE AND DIFFERENTIATED
DOSE
ESCALATION DATA FROM IK-930 PHASE I TRIAL AND REPORTS THIRD
QUARTER 2023 FINANCIAL RESULTS
    * IKENA ONCOLOGY INC: ADDITIONAL IK-930 CLINICAL DATA UPDATE
PLANNED FOR SECOND HALF OF 2024
    * IKENA ONCOLOGY INC: FAVORABLE SAFETY PROFILE IN DOSE
ESCALATION
SHOWN TO DATE FROM TRIAL

Source text for Eikon:  ID:nGNX5Llt48 
Further company coverage:  IKNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))